Gail M. Wilkes, MS, RNC | Authors

August 27, 2012

Vismodegib is for the treatment of adults with metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

May 10, 2012

Treatment of patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

October 19, 2011

Vemurafenib is a protein kinase inhibitor that blocks the mutated gene protein BRAFV600E so that the cascade of messages that drive cell division and prevent apoptosis is stopped, resulting in tumor shrinkage.

July 11, 2011

Ipilimumab blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) and theoretically enables cytotoxic T cells to more effectively attack melanoma cells.

July 11, 2011

Advances in the multidisciplinary management of metastatic colorectal cancer have improved survival considerably, and nurses are key to optimal patient care.

April 18, 2011

Denosumab is an IgG2 monoclonal antibody that inhibits osteoclastic bone resorption (breakdown) via inhibition of RANKL (receptor activator of nuclear factor-kB ligand).

February 16, 2011

After IV administration, the human plasma protein binding of eribulin at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%, and drug is eliminated (mean elimination half-life) in 40 hours.

October 19, 2010

Cabazitaxel is a microtubule inhibitor in the taxane class. It is made from a yew needle precursor using a semisynthetic process. It binds to free tubulin, which is used during mitosis to form two daughter cells.

July 09, 2010

Drug is indicated for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy.

April 12, 2010

Approved Drugs: Pazopanib (Votrient) Indications